Researchers at La Trobe University have built a sensor that mimics the protective surface of gut cells and, in lab tests, tracked drug concentrations in whole blood for 10 hours without losing sensitivity, the researchers report. The team says the device can detect the antibiotic vancomycin at levels up to 100 million times more sensitive than earlier approaches. If the technology translates from bench to bedside, it could give clinicians a more continuous window into how patients metabolize critical medications and potentially reduce reliance on intermittent blood draws used in therapeutic drug monitoring.
Why Blood Destroys Most Sensors
The central problem in continuous blood monitoring is biofouling. Within minutes of contact with whole blood, proteins, platelets, and immune cells coat a sensor’s active surface, smothering its ability to detect target molecules. That buildup is the same foreign-body response that attacks any implant, and it has kept real-time drug tracking largely confined to laboratory prototypes. Separate work at Harvard’s Wyss Institute has documented how anti-biofouling coatings can extend implanted biosensor lifespan, but few designs have demonstrated hours-long stability in undiluted blood rather than diluted or filtered samples.
The La Trobe team’s answer draws directly from biology. Cells lining the gut and mucous membranes survive constant exposure to complex fluids because their outer layers repel unwanted adhesion while still allowing selective molecular exchange. By engineering a sensor surface that replicates those properties, the researchers created a device that resists the protein and cellular buildup that typically degrades electrochemical readings within the first hour of blood contact.
How the Cell-Inspired Design Works
Research co-leader Dr. Mingyu Han from CSIRO explained that the mucosa-inspired coating lets the sensor maintain its electrochemical response even as blood components flow over it. In laboratory tests with undiluted blood, the device held stable readings for 10 hours without the signal drift that plagues conventional designs. Han noted that other sensors had detected vancomycin before, but that this sensor is 100 million times more sensitive, according to La Trobe University.
“Our sensor greatly expands the detection range, allowing us to measure hormones, toxins and other biomarkers that appear only at low concentrations,” the team said in a La Trobe University release. That expanded range matters because many drugs and biomarkers circulate at trace levels that fall below the threshold of standard electrochemical sensors, leaving clinicians blind to early signs that a dose is too high or too low.
Building on a Decade of Aptamer Sensing
The La Trobe device sits at the end of a long research arc in electrochemical aptamer-based sensing. Aptamers are short strands of DNA or RNA engineered to fold around a specific target molecule, and when tethered to an electrode, they generate a measurable electrical signal each time they bind their target. A foundational 2009 study demonstrated continuous cocaine detection using an electrochemical aptamer-based sensor in a complex biological sample, helping establish that aptamer sensors could function beyond simple lab buffers. Related early work on the same platform explored how microfluidic approaches could be paired with electrochemical aptamer sensors to control sample flow and support real-time measurements.
Those early prototypes, however, degraded quickly. Blood proteins fouled their surfaces, and baseline electrical signals drifted as the electrode chemistry changed. At the same time, researchers were refining the basic chemistry of aptamer-based electrochemical switches, including studies of conformational signaling that clarified how folding motions could be translated into robust electrical readouts. These advances helped define how to design aptamers and linkers that remain responsive even as they cycle through many binding and unbinding events in complex fluids.
More recent efforts have attacked both fouling and signal stability directly. A team led by senior author Tom Soh and first author Yihang Chen at Stanford developed a device called SENSBIT, short for Stable Electrochemical Nanostructured Sensor for Blood In situ Tracking. In a university announcement, the group described how nanostructured gold electrodes and tailored surface chemistries allowed the sensor to maintain performance under continuous operation. According to research published in Nature Biomedical Engineering, SENSBIT achieved month-long incubation in undiluted human serum and multi-day function when implanted in a rat femoral vein, showing that electrochemical aptamer sensors could survive in vivo for clinically meaningful periods.
The La Trobe sensor adds a distinct biological strategy to this toolkit. Where SENSBIT relies on rigid nanostructured electrode engineering to resist fouling, the Australian team’s mucosa-inspired coating takes a softer, cell-mimicking approach. Both share the goal of keeping aptamer-based sensors accurate in whole blood over clinically useful time windows, but they arrive there through different material science. The convergence of these approaches suggests that future devices may combine nanostructuring with biomimetic coatings to further extend operating life.
What Continuous Drug Monitoring Could Change
Therapeutic drug monitoring today typically involves drawing a blood sample, sending it to a lab, and waiting hours for results. For drugs with narrow therapeutic windows, like vancomycin, that delay can mean a patient receives too much or too little medication before anyone notices. Vancomycin is widely used against serious bacterial infections, and both underdosing, which risks treatment failure, and overdosing, which can damage kidneys, are well-documented clinical problems.
A sensor capable of tracking vancomycin levels continuously in flowing blood would let clinicians adjust doses in near real time. Separate research on microneedle-based pharmacokinetics has shown that continuous readouts can validate drug absorption and clearance curves that single blood draws might miss, especially during the rapid changes that occur right after a dose. In that work, minimally invasive needles sampled interstitial fluid to reconstruct how drug levels rose and fell over time, pointing toward a future in which real-time data guide dosing decisions.
The La Trobe sensor pushes this vision further by directly targeting whole blood, the matrix in which most therapeutic ranges are defined. If integrated into catheters or extracorporeal circuits, such a device could stream concentration data to bedside monitors, potentially allowing software to flag emerging toxicity or subtherapeutic exposure earlier. For intensive care units managing complex antibiotic regimens, that capability could reduce trial-and-error dose adjustments, though clinical studies would be needed to show whether it improves outcomes such as length of stay.
Beyond Antibiotics: A Platform for Trace Biomarkers
Although vancomycin is the first demonstrated target, the underlying aptamer platform is inherently modular. In principle, swapping in different nucleic acid sequences could retune the sensor to detect chemotherapy agents, immunosuppressants, or even endogenous molecules like hormones. A recent study of electrochemical interfaces emphasized how surface design can determine whether low-abundance biomarkers remain detectable against the dense background of blood proteins. By mimicking mucosal barriers that naturally manage this challenge, the La Trobe approach may generalize to a wide range of analytes that currently require specialized lab assays.
Expanding into multi-drug panels or combined drug–biomarker readouts could be especially valuable in oncology and transplant medicine, where clinicians must balance efficacy against toxicity while tracking organ function. Real-time measurements of both a chemotherapeutic agent and a kidney injury marker, for example, could help oncologists push doses to the edge of safety without crossing it.
From Bench to Bedside
Significant hurdles remain before cell-inspired sensors reach clinical practice. Any implanted or indwelling device must withstand not only hours but days or weeks in circulation, endure mechanical stresses from blood flow, and pass rigorous biocompatibility testing. Manufacturing the mucosa-like coating at scale, with consistent thickness and performance across batches, will also be critical. Regulatory pathways for continuous monitoring tools are still evolving, particularly for systems that might feed into automated dosing algorithms.
Still, the trajectory of the field is clear. Early aptamer sensors proved that nucleic acid switches could function in complex fluids; refinements in conformational design, microfluidic integration, and nanostructured electrodes extended their lifetime and sensitivity; and now, biomimetic coatings are borrowing from the body’s own defenses to survive in whole blood. As these strands of research continue to intertwine, continuous molecular monitoring may move from experimental rigs toward routine clinical tools.
If that happens, future patients on high-risk medications could be watched over by invisible, cell-inspired sentinels in their bloodstream, replacing sporadic snapshots with a continuous, data-rich portrait of how their bodies handle lifesaving drugs.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
